Skip to main content
SpringerLink
Log in

Esaxerenone: First Global Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Esaxerenone (MINNEBRO™)—a novel oral, non-steroidal, selective mineralocorticoid receptor blocker—is being developed by Daiichi Sankyo for the treatment of hypertension and diabetic nephropathies. In January 2019, based on positive results from a phase III trial conducted in Japan in patients with essential hypertension, esaxerenone received marketing approval in Japan for the treatment of hypertension. This article summarizes the milestones in the development of esaxerenone leading to this first global approval for the treatment of hypertension.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mulatero P, Milan A, Williams TA, et al. Mineralocorticoid receptor blockade in the protection of target organ damage. Cardiovasc Hematol Agents Med Chem. 2006;4(1):75–91.

    Article  CAS  Google Scholar 

  2. Kato M, Furuie H, Shimizu T, et al. Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects. Br J Clin Pharmacol. 2018;84(8):1821–9.

    Article  CAS  Google Scholar 

  3. Shibata S, Ishizawa K, Uchida S. Mineralocorticoid receptor as a therapeutic target in chronic kidney disease and hypertension. Hypertens Res. 2017;40(3):221–5.

    Article  CAS  Google Scholar 

  4. Daiichi Sankyo. Esaxerenone (Minnebro): Japanese prescribing information; 2019. http://www.pmda.go.jp/PmdaSearch/iyakuDetail/430574_21490B6F1026_1_02#CONTRAINDICATIONS. Accessed 15 Jan 2019.

  5. Daiichi Sankyo. Daiichi Sankyo announces approval of MINNEBRO™ tablets for the treatment of hypertension in Japan [media release]. 8 Jan 2019. https://www.daiichisankyo.com.

  6. Ito S, Ito H, Rakugi H, et al. A double blind phase III study of esaxerenone (CS-3150) compared to eplerenone in patients with essential hypertension (ESAX-HTN study). J Hypertens. 2018;36(Suppl 1):e239.

    Article  Google Scholar 

  7. Daiichi Sankyo. Sankyo and Exelixis sign joint research agreement [media release]. 23 Mar 2016. https://www.sec.gov/Archives/edgar/data/1340156/000119312506061375/dex991.htm.

  8. Exelixis. Exelixis announces first quarter 2006 financial results [media release]. 9 May 2006. http://www.exelixis.com.

  9. Arai K, Homma T, Morikawa Y, et al. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Eur J Pharmacol. 2015;761:226–34.

    Article  CAS  Google Scholar 

  10. Arai K, Morikawa Y, Ubukata N, et al. CS-3150, a novel nonsteroidal mineralocorticoid receptor antagonist, shows preventive and therapeutic effects on renal injury in deoxycorticosterone acetate/salt-induced hypertensive rats. J Pharmacol Exp Ther. 2016;358(3):548–57.

    Article  CAS  Google Scholar 

  11. Arai K, Tsuruoka H, Homma T. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. Eur J Pharmacol. 2015;769:266–73.

    Article  CAS  Google Scholar 

  12. Yamada M, Mendell J, Takakusa H, et al. Pharmacokinetics, metabolism, and excretion of [14C]esaxerenone, a novel mineralocorticoid receptor blocker in humans. Drug Metab Dispos. 2019;47(3):340–9.

    Article  CAS  Google Scholar 

  13. Ito S, Ito H, Rakugi H, et al. Treatment with esaxerenone (CS-3150) is associated with a significant dose dependent antihypertensive effect in essential hypertensive patients [abstract no. BP.02.01]. J Hypertens. 2017;35(Suppl 2):e173.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Sean Duggan

Authors
  1. Sean Duggan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sean Duggan.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sean Duggan is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Duggan, S. Esaxerenone: First Global Approval. Drugs 79, 477–481 (2019). https://doi.org/10.1007/s40265-019-01073-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-019-01073-5

Search

Navigation